2026-08-08 · equities
The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%
Quick Read
-
ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat.
-
ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting the market overcorrected on the category leader.
-
Bernstein's $685 target implies 83% upside with the bull case hinging on the da Vinci 5 upgrade cycle mirroring the prior seven-year Xi ramp.
-
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Intuitive Surgical didn't make the cut. Grab the names FREE today.
Intuitive Surgical (NASDAQ:ISRG) trades at $373.71, while the average Wall Street price target sits at $477.25. That leaves the stock roughly 28% below consensus, and Bernstein pegs fair value at $685, implying returns north of 83%.
Intuitive Surgical dominates the robotic-assisted surgery market with its da Vinci surgical system and Ion lung biopsy platform. It has an installed base of 11,710 da Vinci systems worldwide. Wall Street has treated it as a compounder for years, making the current gap between price and target notable.
How A Compounder Lost A Third Of Its Value
ISRG is down 34.02% year to date and 21.17% over the past twelve months. The trigger was a slower guide, not a broken business. Full-year 2026 da Vinci procedure growth was set at 13.5% to 15.5%, a clear deceleration from the roughly 18% pace investors expected.
Tariffs compounded the damage. Instruments and accessories are manufactured in Mexico, endoscopes in Germany, and certain materials come from China. Management embedded a 1.0% revenue drag from tariffs into gross margin guidance and warned further escalation could materially hit results. HSBC downgraded the stock from Buy to Hold and cut its target from $604 to $391. A Class II recall of 11,113 da Vinci SP drapes added noise, and moderation in U.S. elective procedures tied to ACA subsidy expiration finished the decline.
Why The Bulls Are Still On Board
Analysts remain bullish because the underlying business kept beating expectations through the selloff. Q2 2026 non-GAAP EPS came in at $2.80 versus a $2.50 consensus, revenue of $2.89 billion grew 18.5% year over year, marking the fifth consecutive quarterly beat. Non-GAAP gross margin expanded to 70.0% from 67.9%.
The bull thesis rests on the da Vinci 5 upgrade cycle. Placements hit 246 dV5 systems in Q2, and CFO Jamie Samath compared the trajectory to the Xi cycle, which "took about seven years before we got to the peak trade-in volumes.". Add a growing recurring instruments base, $8.63 billion in cash, and an extended-use instrument program rolling out in 2027. The rating mix shows 7 analysts rate ISRG Strong Buy, 16 Buy, 9 Hold, and just 1 Sell.